1. Home
  2. GBIO

GBIO

Generation Bio Co.

Logo Generation Bio Co.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Founded: 2016 Country:
United States
United States
Employees: 174 City: CAMBRIDGE
Market Cap: 246.0M IPO Year: 2020
Target Price: $8.00 AVG Volume (30 days): 251.9K
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.96 EPS Growth: N/A
52 Week Low/High: $0.86 - $6.98 Next Earning Date: 05-08-2024
Revenue: $5,904,000 Revenue Growth: N/A
Revenue Growth (this year): -55.83% Revenue Growth (next year): -9.28%

Share on Social Networks: